Compare LVO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVO | CING |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.9M | 64.5M |
| IPO Year | 2010 | N/A |
| Metric | LVO | CING |
|---|---|---|
| Price | $4.49 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $34.50 |
| AVG Volume (30 Days) | 42.7K | ★ 218.6K |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,144,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $3.16 |
| 52 Week High | $7.19 | $11.89 |
| Indicator | LVO | CING |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.94 |
| Support Level | N/A | $4.21 |
| Resistance Level | N/A | $5.15 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 83.23 |
LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world'wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. The Company's operations are based in the United States.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.